Randomized Implementation of a Primary Human Papillomavirus Testing-based Cervical Cancer Screening Protocol for Women 34 to 69 Years in Norway

被引:8
|
作者
Nyga, Mari [1 ,11 ]
Engesaeter, Birgit [1 ]
Castle, Philip E. [2 ,3 ]
Berland, Jannicke Mohr [4 ]
Eide, Maj Liv [5 ]
Iversen, Ole Erik [6 ,7 ]
Jonassen, Christine Monceyron [8 ]
Christiansen, Irene Kraus [9 ]
Vintermyr, Olav Karsten [7 ,10 ]
Trope, Ameli [1 ]
机构
[1] Canc Registry Norway, Oslo, Norway
[2] NCI, Div Canc Prevent, NIH, Rockville, MD USA
[3] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA
[4] Stavanger Univ Hosp, Stavanger, Rogaland, Norway
[5] Trondheim Reg & Univ Hosp, Trondheim, Norway
[6] Univ Bergen, Inst Clin Sci, Bergen, Norway
[7] Haukeland Hosp, Bergen, Norway
[8] Ostfold Hosp Trust, Ctr Lab Med, Gralum, Norway
[9] Akershus Univ Hosp, Lorenskog, Norway
[10] Univ Bergen, Gades Lab Pathol, Bergen, Norway
[11] Canc Reg istry Norway, Res Dept, Postbox Majorstuen 5313, N-0304 Oslo, Norway
关键词
INTRAEPITHELIAL NEOPLASIA; FOLLOW-UP; CYTOLOGY; RISK; PREVENTION; TRIAGE;
D O I
10.1158/1055-9965.EPI-22-0340
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cervical cancer screening programs are facing a programmatic shift where screening protocol based on human papillomavirus testing (HPV-Screening protocol) is replacing the liquid-based cytology (LBC-Screening protocol). For safe technol-ogy transfer within the nationwide screening programme in Nor-way, HPV-Screening protocol was implemented randomized to compare the real-world effectiveness of HPV-Screening protocol and LBC-Screening protocol at the first screening round. Methods: Among 302,295 women ages 34 to 69 years scheduled to attend screening from February 2015 to June 2017, 157,447 attended. A total of 77,207 were randomly allocated to the HPV-Screening protocol and 80,240 were allocated to the LBC-Screening protocol. All women were followed up for 18 months. Results: The HPV-Screening protocol resulted in a relative increase of 60% in the detection of cervical intraepithelial neoplasia (CIN) grade 2 or worse [risk ratio (RR) = 1.6, 95% confidence interval (CI) = 1.5-1.7], 40% in CIN grade 3 or worse (RR = 1.4, 95% CI = 1.3-1.6), 40% in cancer (RR = 1.4, 95% CI = 1.0-2.1), and 60% in colposcopy referrals (RR = 1.6, 95% CI = 1.5-1.6) compared with LBC-Screening. The perfor-mance of both protocols was age dependent, being more effective in women ages under 50 years. Conclusions: The HPV-Screening protocol was well accepted by women in Norway and detected more CIN2, CIN3, and cancers compared with the LBC-Screening protocol.Impact: A randomized implementation of the HPV-Screening protocol with real-world assessment enabled a gradual, quality assured, and safe technology transition. HPV-based screening protocol may further be improved by using HPV genotyping and age-specific referral algorithms.
引用
收藏
页码:1812 / 1822
页数:11
相关论文
共 50 条
  • [1] Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway
    Burger, E. A.
    Ortendahl, J. D.
    Sy, S.
    Kristiansen, I. S.
    Kim, J. J.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (09) : 1571 - 1578
  • [2] Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway
    E A Burger
    J D Ortendahl
    S Sy
    I S Kristiansen
    J J Kim
    [J]. British Journal of Cancer, 2012, 106 : 1571 - 1578
  • [3] Human papillomavirus testing for primary cervical cancer screening
    Meijer, CJLM
    Rozendaal, L
    vanderLinden, JC
    Helmerhorst, TJM
    Voorhorst, FJ
    Walboomers, JMM
    [J]. NEW DEVELOPMENTS IN CERVICAL CANCER SCREENING AND PREVENTION, 1997, : 338 - 347
  • [4] Human papillomavirus testing for primary cervical cancer screening
    Grce, Magdalena
    Davies, Philip
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2008, 8 (05) : 599 - 605
  • [5] Human papillomavirus testing for primary cervical cancer screening
    Carolyn D. Runowicz
    Stephanie Garozzo
    [J]. Current Oncology Reports, 2008, 10
  • [6] Human Papillomavirus Testing for Primary Cervical Cancer Screening
    Runowicz, Carolyn D.
    Garozzo, Stephanie
    [J]. CURRENT ONCOLOGY REPORTS, 2008, 10 (06) : 533 - 537
  • [7] Human papillomavirus testing for primary cervical cancer screening
    Cuzick, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (01): : 108 - 109
  • [8] Women's intentions to receive cervical cancer screening with primary human papillomavirus testing
    Ogilvie, Gina S.
    Smith, Laurie W.
    van Niekerk, Dirk J.
    Khurshed, Fareeza
    Krajden, Mel
    Saraiya, Mona
    Goel, Vivek
    Rimer, Barbara K.
    Greene, Sandra B.
    Hobbs, Suzanne
    Coldman, Andrew J.
    Franco, Eduardo L.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (12) : 2934 - 2943
  • [9] Cervical cancer prevention: Human papillomavirus testing as primary screening
    Desai, Shreya
    Zhu, Michelle J.
    Lapidos-Salaiz, Ilana
    [J]. CANCER, 2022, 128 (05) : 939 - 943
  • [10] Human papillomavirus testing for primary screening of cervical cancer precursors
    Ratnam, S
    Franco, EL
    Ferenczy, A
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2000, 9 (09) : 945 - 951